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Abstract
Purpose—To develop, operationalize, and pilot test a transparent, reproducible, and evidence 
informed method to qualify when to report incidental findings from next generation sequencing 
technologies.
Methods—Using evidence-based principles, we propose a three stage process. Stage I ‘rules out’ 
incidental findings below a minimal threshold of evidence and is evaluated using inter-rater 
agreement and comparison with an expert-based approach. Stage II documents criteria for clinical 
actionability using a standardized approach to allow experts to consistently consider and 
recommend whether results should be routinely reported (Stage III). We used expert opinion to 
determine the face validity of Stages II and III using three case studies. We evaluated the time and 
effort for Stages I and II.
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Results—For Stage I, we assessed 99 conditions and found high inter-rater agreement (89%), 
and strong agreement with a separate expert-based method. Case studies for familial adenomatous 
polyposis, hereditary hemochromatosis, and α1-Antitrypsin Deficiency were all recommended for 
routine reporting as incidental findings. The method requires less than three days per topic.
Conclusion—We establish an operational definition of clinically actionable incidental findings 
and provide documentation and pilot testing of a feasible method that is scalable to the whole 
genome.
Keywords
whole genome sequencing; clinical actionability; population screening; secondary findings; whole 
exome sequencing
INTRODUCTION
Use of next generation sequencing (NGS) technologies in clinical medicine and research is 
increasing, with tens of thousands of human genomes now completed.1 The decreasing cost 
of generating whole genome or whole exome sequence (WGS, WES) data using NGS 
platforms means that it may soon be less expensive to routinely sequence the entire genome 
than to use many more targeted assays.2 Thus, we are rapidly approaching a time when 
genome-scale sequencing tests may be analytically robust, clinically relevant and affordable 
enough to replace the single gene tests currently used in clinical practice.
These new technologies allow for a vast proportion of an individual’s DNA to be queried, 
raising the issue of genomic incidental findings (IFs—unanticipated information discovered 
in the course of testing or medical care). 3 IFs will inevitably arise when NGS is not 
restricted to portions of the genome that are relevant to the indication for the test. Individual 
genomes that have been evaluated using WGS indicate that there are typically over 4 million 
variants observed per person compared with the reference sequence.4–9 Each person carries 
an average of 50 to 100 heterozygous variants classified by the Human Gene Mutation 
Database as causing inherited disorders, although emerging information suggests that most 
of these are incorrect assertions of pathogenicity and/or errors of curation.10,11 Without 
thoughtful interpretation, it would be a daunting task to return this information to patients in 
ways that would be helpful and accurate.12
While the number of clinically relevant IFs that could result from each sequence generated 
remains unclear, questions about the capacity of laboratories, providers, and health systems 
to manage the interpretation and presentation of findings to patients remain pertinent.3,13 
Because of the unprecedented ability of NGS to identify variants across the entire genome, 
most IFs will have unknown clinical significance. A process and criteria are needed to 
organize the return of results from IFs to enable end users to focus on the small number of 
clinically relevant variants.
Berg and colleagues proposed a framework for a priori categorization of genomic loci into 
three “bins” for management of IFs.14 Any given individual will have few or no clinically 
actionable IFs (Bin 1).11 These results should have well understood and validated 
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associations between genotype and phenotype, and are clinically actionable, meaning that 
interventions could delay or prevent manifestations, or health outcomes could be improved 
through early identification and treatment. IFs that are clinically valid but not actionable 
(Bin 2) are likely to be slightly more numerous.11 These results have well understood and 
validated associations between genotype and phenotype, but are not immediately clinically 
actionable. Examples include variants relevant to pharmacogenomics (which only become 
actionable when a relevant drug is prescribed), most single gene disorders, and risk alleles 
such as APOE genotype for Alzheimer’s disease risk (for which there is not yet effective 
prevention or treatment). Although some patients may be interested in receiving information 
about these IFs, Berg and colleagues argued that their return should not be automatic since 
the knowledge would not definitely improve health outcomes, and some results could result 
in psychosocial harms. Most genomic loci will fall into the third category of uninformative 
IFs (Bin 3), where there is an insufficient knowledge base on the association between 
genotype and phenotype. These IFs would typically not be considered for return of results in 
a clinical setting.
Several initiatives have begun to guide decisions about which IFs to return to patients or 
research participants from NGS platforms. At least three initiatives have been sponsored by 
the National Human Genome Research Institute including the electronic medical records and 
genomics (eMERGE) Network,15 the Clinical Sequencing Exploratory Research (CSER) 
consortium, and the Return of Results (ROR) consortium. Professional organizations have 
established committees to assess NGS platforms (e.g., College of American Pathologists16 
and the American College of Medical Genetics and Genomics2). For the past 8 years, the 
CDC Office of Public Health Genomics has supported the independent Evaluation in 
Genomic Applications in Practice and Prevention (EGAPP) Working Group to develop 
evidence based recommendations on the use of genomic tests in clinical practice and disease 
prevention.17 The EGAPP Working Group (EWG) sponsored and guided the Knowledge 
Synthesis Center (KSC) to develop a process to determine which gene/condition pairs 
belong in the category of clinically actionable IFs in adults. The KSC collaborated with 
several members of the Working Group to extend the framework proposed by Berg and 
colleagues, by clarifying and operationalizing criteria for determining clinically actionable 
IFs. The method includes a structured process to identify evidence, consider the evidence 




We adapted the conceptual framework of population screening, which includes ethical, 
procedural, and statistical considerations. A higher standard is needed in the case of 
screening because the pre-test probability is low, which affects the likelihood that a detected 
mutation is a true health-impairing variant. There must be at least moderate certainty that 
screening-based identification of the gene/condition and subsequent management has been 
shown to have a net benefit—that health benefits will outweigh potential harms.18
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Typically, screening tests should be held to a very high standard, with clinical19,20 
recommendations made only after a thorough, systematic review of the available evidence. 
A systematic review of each gene mutation would not be an effective or efficient approach, 
due to the sizeable, very active, but largely developmental clinical research base. Therefore, 
pragmatic choices were made to increase the feasibility and scalability of the method to the 
entire genome, such as limiting the sources that would be considered (i.e., a reproducible but 
not comprehensive search for evidence).21 Our approach is influenced by the principles of 
systematic reviews, including: 1) the need for a priori objective criteria upon which to make 
decisions; 2) an emphasis on transparency and reproducibility of decision-making; 3) clear 
and transparent communication of methods and results; and 4) clear procedures to allow 
results to be revised as new evidence emerges. To develop these criteria, we considered 
published articles on population screening in general, newborn screening, or screening for 
specific genetic conditions.22–32
Our method is composed of three distinct stages. In stage I, we define rule-out criteria to 
rapidly eliminate genes/conditions that do not meet a baseline threshold. In stage II, genes/
conditions that pass this initial threshold are subjected to a more resource intensive search of 
the literature with the relevant evidence synthesized into a short summary. In stage III, 
decision makers consider the summary for final selection of clinically actionable IFs.
Method Evaluation
Rater Agreement in Stage I—We evaluated the same 99 conditions selected by Green et 
al.12 to assess the method for stage I. The 99 conditions were primarily selected from the 
GeneTests website (http://www.ncbi.nlm.nih.gov/sites/GeneTests/), based on the frequency 
of laboratory testing, among other considerations. Each condition was evaluated 
independently by two raters (K.G., J.W., E.M.W., K.S., H.F., D.C.O., or J.S.B.) and 
categorized as retained or ruled out. We calculated overall agreement and Cohen’s kappa33 
as measures of inter-rater agreement. We adjudicated disagreements by discussion among 
raters to clarify reasons for disagreement, and erred towards ‘retain’ if there was ambiguity.
External Validity—We compared the categorization of the 99 conditions for stage I 
(retain/rule out) to the findings of an expert-based approach, which we refer to as the Green 
method.12 In the Green method, 16 specialists (including J.S.B.), including clinical 
geneticists and molecular laboratory directors, evaluated 99 conditions as to whether they 
would routinely disclose or not disclose the information when discovered as an IF. 
Specialists were asked to assume the sequencing was perfectly accurate, family history was 
not available, the patient had no previously recognized clinical features consistent with the 
disease variant under consideration, the patient’s sex was known, and the patient was an 
adult, but the exact age was unknown. Each specialist recorded their response independently 
(with no explicit guidelines regarding clinical actionability) The overall results were 
reported as the proportion of specialists who responded to ‘disclose’ the finding, which 
ranged from 50–100% across the 99 conditions. We infer that conditions with a high level of 
concordance among these experts represent those with the highest degree of clinical 
actionability and thus agreement that such information would be important to return as IFs.
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We assume an adult patient has received WGS or WES as part of their clinical care for an 
unspecified indication, and the sequencing has acceptable analytic validity. Sex is known, 
but not the patient’s specific age, or any other personal or familial medical history. The 
patient is currently undiagnosed with the condition under consideration. This criterion does 
not imply that the patient is asymptomatic. Asymptomatic patients are either ‘disease-free’ 
or the condition is present, but the physical signs are ‘undetected’ by the patient or their 
clinician (e.g. tumors or precursor lesions may be present years before cancer symptoms 
appear). Symptomatic patients can also have symptoms that are non-specific, so the genetic 
condition is ‘unrecognized’. For instance, a patient may be aware of and receive treatment 
for high cholesterol, but they may be unaware that they carry a mutation that causes familial 
hypercholesterolemia. All of these scenarios–disease-free, undetected disease, and 
unrecognized disease–are part of a spectrum of undiagnosed patients.
RESULTS
Stage I
The purpose of stage I is to eliminate genes/conditions from further consideration that do not 
meet a minimal threshold of clinical actionability. We expect a large majority of genes/
conditions will be ruled out in this stage. Stage I has three pre-defined criteria addressed in 
five questions (Table 1). The three criteria are: 1) actionability, 2) moderate or high 
penetrance, and 3) association with a significant health condition. The criteria for stage I are 
documented on the Binning Dashboard (Supplemental Table 1). If any of the three criteria 
are not met, the gene/condition is excluded from further consideration. For each gene/
condition it is most efficient to begin with an area suspected to not meet the criteria.
References used to assess the criteria include existing guidelines, systematic reviews, or 
expert-derived guidance [Table 2]. These resources are identified using a predefined method 
for searching existing databases for related materials. Only one reference is required to meet 
any given criteria. Thus, the search procedure is focused and not necessarily comprehensive.
This stage requires high sensitivity, so the gene/condition should be retained when it is 
uncertain if the minimum threshold is met. Two reviewers assess each gene/condition 
independently. Discrepant findings are adjudicated by consensus with additional input from 
a third party, as needed.
Criteria 1: Actionability—For disease-free patients, actionability implies an effective 
intervention to delay or prevent clinical manifestations or reduce disease impact. For 
patients with undetected disease, actionability includes screening for earlier diagnosis and to 
increase the likelihood of less burdensome disease. For symptomatic (but clinically 
unrecognized) patients, actionability includes alterations in patient management proven to 
provide benefit. Other actions include family management to improve outcomes for family 
members (referral to genetic services, or reproductive decision-making alone is not 
sufficient), or avoidance of circumstances for the patient (e.g., behavioral modifications, 
diet, exercise, smoking cessation).
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Sufficient support of actionability is derived from a practice guideline, expert-derived 
guidance, or a systematic review. If no such guidance or review exists, our process defines 
the gene/condition pair as not actionable. If a guideline or systematic review is available, but 
only recommends care once symptoms have manifested, then the actionability criteria has 
not been met for an undiagnosed adult. If clinical signs and symptoms would always be 
recognized in childhood or early adolescence, the condition is not considered actionable in 
adults.
Criteria 2: Penetrance—At least one variant in the gene(s) under consideration should 
have high or moderate penetrance or risk in any population. We selected an arbitrary 
threshold for the penetrance of either 40% or a measure of relative risk of 2 or greater. 
While the absolute penetrance for a condition may be low, the relative risk compared with 
the general population may still be significant. For example, the penetrance of C282Y 
homozygosity in the HFE gene is 13.5% for the development of hereditary 
hemochromatosis;34 however, the odds ratio for liver disease is 3.9 and up to 11 for 
hepatocellular carcinoma.35 Penetrance data from studies in affected individuals may be 
used if data from an unselected population is not available. If the data regarding penetrance 
is unavailable, and all other criteria are met, the gene/condition should be retained to stage 
II.
Criteria 3: Significance/Burden of Condition—The condition should cause 
significant morbidity or mortality in adults. This does not include normal human variation 
such as eye color, hair color, skin color, or body size measurements such as height. We do 
not address infertility alone or reproductive decision making as part of this approach, 
recognizing that these could be important in some settings.
Agreement in Stage I
The inter-rater agreement was substantial with an overall agreement of 89% and a kappa of 
0.70. Both reviewers retained 55 and both ruled-out 30 of the 99 conditions. For the 14 
conditions where the reviewers disagreed, the reasons were: 4 disagreements about the 
presence or absence of a guideline, 1 disagreement about the overall actionability, 3 
disagreements about the actionability in adults, 5 disagreements about whether the 
penetrance was high/moderate or low, and 1 disagreement about multiple areas. After 
resolving the disagreements, 62 gene/conditions were retained to stage II.
External Validity of Stage I
The results of the Stage I evaluation compared favorably with the expert-based Green 
method (Table 3). In most (88%) conditions that we retained after stage I, a high percentage 
(≥ 88%) of experts also agreed to recommend disclosure. Likewise, most conditions (92%) 
that we ruled-out after stage I similarly had lower agreement (<70%) among experts to 
disclose. When examining 37 conditions with only moderate agreement (75–81%) between 
experts in the Green method, we retained an intermediate proportion (46%), and 9 out of 14 
disagreements between reviewers in our method were among these 37 conditions.
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We ruled out six conditions that a high percentage (≥ 88%) of experts selected to disclose in 
the Green method. Four of these conditions (retinoblastoma, neurofibromatosis 1, MCAD 
deficiency, and isovaleric acidemia) have predominantly childhood onset, and are unlikely 
to present in an undiagnosed adult. One condition is not actionable (Tay Sachs disease), and 
one condition is not actionable in adults (Beckwith-Wiedemann Syndrome). Thus, none of 
these genes/conditions were deemed likely to ultimately fulfill the criteria of clinically 
actionable IFs had they been retained in stage II, and the apparent discrepancy between our 
results and the Green method does not indicate a serious problem with our method.
Stage II
The purpose of stage II is to document and summarize the readily available evidence related 
to key features of actionability to evaluate candidates for a clinically actionable IF. Although 
a relatively high bar for clinical actionability must be met for a gene/condition pair to 
qualify for routine reporting, we specify a relatively low threshold for the type of evidence 
that is permitted, including non-systematic or expert-based references. This approach is both 
pragmatic and efficient as this represents the most common available evidence for highly 
penetrant rare genetic conditions. There is transparency in the level of evidence by 
documenting the relative strength using a tiered system (Table 4) and quality rating the 
evidence reference using existing methods.36,37
In Stage II we conduct a reproducible search of existing synthesized literature using the 
predefined method (Table 2). Once a full search for potentially relevant references is 
completed, we examine these references to determine relevance. Any references deemed 
irrelevant are excluded.
To assess the relative quality of the identified references, we place each reference into one 
of four tiers (Table 4). The tiers are used to facilitate a hierarchical method for examining 
existing literature, starting with the most evidence-based. Different tiers of evidence can be 
present in the same document. For example, background information in a systematic review 
is not subjected to the same methods as data from the actual review questions.
We then produce a narrative summary with standardized information that is abstracted and 
documented for each gene/condition (Table 1; Supplemental Table 2). For each question, we 
use the reference(s) with the highest available tier of evidence for data abstraction. All 
sources are referenced if they are in agreement. If not, the reviewer determines the best 
reference based on considerations including quality, methods (e.g., search strategy, inclusion 
criteria, analytic methods, funding source), and date of publication (e.g., more recent 
publications may be more relevant). If there is not a best reference, we abstract data from all 
relevant references. The tier of evidence is recorded for each abstracted data element.
References are quality rated only if they are used as a reference for at least one question in 
the summary report, and there is a discrepancy between references. Thus, quality rating 
serves as a ‘tie breaker’ when we cannot otherwise decide on a best reference. For 
systematic reviews (Tier 1), we use the AMSTAR method.37 For practice guidelines (Tier 
2), we use the AGREE II method.36 Quality rating for tiers 3 and 4 is not performed, 
because there is not an established method.
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Stage II Case Studies
We conducted case studies for Familial Adenomatous Polyposis (FAP, Supplemental Table 
3), Hereditary Hemochromatosis (HH, Supplemental Table 4), and α1-Antitrypsin 
Deficiency (AAT, Supplemental Table 5). These topics were selected to represent a 
spectrum in the expert opinion on clinical actionability. For each condition, we identified 
between 31 and 46 references, of which 13 to 30 were relevant to the topic (Table 5). About 
40–50% of the relevant references were Tier 1, and 5 to 10 references were cited in each 
summary document. We did not complete the quality rating for any of these three topics, 
because no ‘tie breakers’ were needed.
Resource requirements for Stage I and Stage II
We estimated the resource requirements to complete these evaluations on a genome wide 
scale. We assume 2000 topics for review at Stage I; each topic is dual-reviewed and requires 
one hour to complete per person, and 25% of topics require adjudication of disagreements 
(15 minutes each for two people). Under these assumptions, stage I would require slightly 
more than two full time employees for one year. For Stage II, we assume that at most 25% 
of the 2000 topics in Stage I are retained, and each topic takes between 12 to 20 hours to 
complete. Stage II requires three to five full time employees for a year.
Stage III
The purpose of stage III is for a decision-making panel of experts to review the evidence in 
the summary document and make decisions about clinically actionable IFs. Different 
decision-making bodies may come to different decisions on which IFs should be routinely 
reported. Panels are convened by various stakeholders including professional organizations, 
payers, and governmental agencies. One such panel is the EWG, which has broad 
experience in methods development and making recommendations for genomic 
applications.17,38,39 We presented the three case studies to the EWG. In each example, the 
group had consensus that the methodology produced sufficient documentation to decide that 
all three conditions are clinically actionable and IFs should be routinely reported 
(Supplemental Tables 3–5).
DISCUSSION
We have presented a transparent, reproducible, efficient, and evidence informed process for 
identifying clinically actionable IFs in adults. This work builds upon an established 
framework11 by operationalizing the categorization of clinically actionable IFs.14 We 
implemented the method in stage I for 99 conditions, and demonstrated both high inter-rater 
agreement (89%) and external validity compared with the Green et al. expert-based 
approach. While the Green method is not a gold standard, it is the only published method 
available for comparison. We pilot-tested the method using three case studies for stages II 
and III, which showed that the evidence summaries provided sufficient information for the 
EWG to recommend clinically actionable IFs that should be routinely reported. The process 
is scalable to the whole genome, and can be completed within a year for 2000 gene/
condition pairs by about two people for Stage I and three to five people for Stage II.
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As genome-scale sequencing tests are more routinely incorporated into clinical care, the 
ability to centralize the determination of clinically actionable IFs in a transparent and 
reproducible way is critical. Clinicians cannot be expected to individually assess the 
evidence across the entire genome, and then make individual determinations about returning 
IFs. Methods such as this one could facilitate centralized recommendations that can be 
confidently adopted by clinical laboratories and physicians, resulting in more consistent care 
across providers. Also, the evidence base is rapidly developing, so the need for transparency 
in decisions as to why gene/conditions are not clinically actionable supports updating 
recommendations as new information becomes available. Guidance on the appropriate 
reporting of IFs is relevant to many stakeholder groups.
Our method, while grounded in evidence-based principles, is also pragmatic in that it allows 
consideration of both expert-based and evidence-based guidelines. This approach recognizes 
the still-limited clinically relevant evidence on genetic mutations for most conditions, and 
the fact that very rare conditions may never accumulate the level of evidence required for 
traditional evidence-based practice guidelines. Our use of tiers to indicate the relative 
strength of the methodology used for reference documents allows flexibility for decision-
makers. For example, if the usual presentation is sudden death, decision-makers might 
accept a low threshold of evidence in favor of prevention. The method provides balance 
through consideration of the potential risks and burdens, as well as benefits of interventions. 
Our approach uses consistent, but not comprehensive, search strategies to identify already 
summarized or synthesized evidence, allowing the method to be scalable to the whole 
genome. This systematic method would be made even more acceptable if combined with 
opportunities for public input, so that any non-reportable gene/condition pair can be revised 
with the availability of new (or overlooked) information, a practice that has been used by 
PLoS Currents/Genomic Tests (http://currents.plos.org/genomictests/).
There are several limitations of the proposed approach. Further experience, including 
clarification for some of the criteria, would strengthen the method. Semi-quantitative 
measures of the elements of actionability would avoid subjective interpretation of these 
criteria and facilitate thresholds to determine actionability. Evidence will change over time 
with advances in medical genetics, necessitating re-evaluation of genes/conditions. To 
account for these changes, the method needs an approach for updating and consideration of 
raised objections. The proposed method is conservative in assuming that no personal or 
family history information will be available to guide interpretation. Individual results will 
need to be contextualized by a clinician with expertise in genetics in order to personalize the 
interpretation.
This method is completely agnostic to the specific technology used to detect any given 
variant. Thus, we consider the assessment of analytic validity of molecular testing platforms 
as a necessary, but separate, issue. Although we do not intend to implement the method at 
the level of specific variants, in clinical practice variants within genes will need to be 
classified as deleterious or benign. This topic is being addressed by clinical laboratories and 
efforts such as ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) and the Human Variome 
Project (http://www.humanvariomeproject.org/).
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This work is an important step toward identifying clinically actionable IFs on a genome-
wide scale. Future work is needed to confirm our findings by applying all three stages to 
more cases and to address situations that were outside the scope of this work. Berg and 
colleagues explicitly recognize a category of variants that are clinically validated but not 
actionable (Bin 2), which can be further subdivided into categories based on the risk of 
psychosocial harm. The proposed method does not address how to classify IFs within this 
category NGS technology will likely be used in clinical settings that we did not address, 
including reproductive decision making, newborn screening, and pediatric cases. These 
scenarios will need significant revision of the method to address them. The method may 
achieve the widest adoption if the acceptability of the criteria and staged approach is 
assessed among diverse stakeholders, and potentially modified (e.g., selecting different 
thresholds) to include different perspectives. Nevertheless, we expect that application of this 
method will result in a robust framework for the subsequent analysis and management of IFs 
from individual genome-scale sequencing assays.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1




Is there a practice guideline or systematic review for the genetic condition?
Does the practice guideline or systematic review indicate that the result is actionable in one or more of the 
following ways: a) patient management, b) surveillance or screening, c) family management, or d) 
circumstances to avoid?
Is the result actionable in an undiagnosed adult with the genetic condition?
Penetrance Is there at least one known pathogenic variant with at least moderate penetrance (≥40%) or moderate relative risk (≥2) for important health implications in any population?




What is the nature of the threat to health for an individual carrying a deleterious allele?
Disease Incidence Disease Prevalence
Clinical Features (Signs/Symptoms) Natural History
Significance/Burden of Condition
Actionability
How effective are available interventions for preventing the harm?
Patient Management Surveillance
Family Management Circumstances to Avoid
Penetrance
What is the chance that this threat will materialize?
Prevalence Penetrance
Expressivity Relative Risk
Acceptability of Intervention How acceptable are available interventions in terms of the burdens or risks placed on the individual?
Risks
Would the underlying risk or condition escape detection prior to harm in the setting of recommended care?
Chance to escape clinical detection in adults
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Table 2
Search method to identify references of evidence based practice guidelines, systematic reviews, or expert 
consensus based practice guidelines. For stage I, these steps are completed only until at least one relevant 
reference is identified. For stage II, all steps are completed to identify a comprehensive list of references based 
on this search method.
Step Method
1
Identify synonyms for the condition, name of involved gene(s), and the OMIM identification number from the following sites:
OMIM: http://www.ncbi.nlm.nih.gov/omim
GeneTest Review: http://www.ncbi.nlm.nih.gov/sites/GeneTests/review
2 If a GeneTest review exists, search for a link to a treatment guideline within the text (e.g., a “Guideline” flag) or reference list.
3 Search OMIM for a link to a guideline.
4 Search guidelines.gov for condition name and any synonyms identified in step 1.
5
In Pubmed: Select MeSH from the search pull down menu. Search for the condition. In the list of results select the one that is relevant. 
On the right side select “Add to search builder” and then “search pubmed”. On the side under article types select “practice guidelines” 
and “systematic reviews”.
6
If no relevant MeSH term is identified using the condition name see if MeSH terms exist for the synonyms, individual genes, or a 
larger category that the disease might fall under (e.g., inborn errors of metabolism). If no terms are identified or the term is too broad, 
search Pubmed using the condition or gene name as text words and limit article types to “practice guidelines” and “systematic 
reviews”.
7
Consider the following sources if no systematic reviews or practice guidelines are identified in the previous steps:
OrphaNet: http://www.orpha.net/consor/cgi-bin/index.php
Clinical Utility Gene Cards: http://www.nature.com/ejhg/archive/categ_genecard_012011.html
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Table 3
External validity compared with expert opinion-based method by Green et al.12
Green Method Proposed Method*
% Responded yes, disclose Retain Rule–out Total
100% 20 (95%) 1 21
94% 11 (78%) 3 14
88% 13 (87%) 2 15
81% 6 8 (43%) 14
75% 11 12 (45%) 23
69% 0 6 (100%) 6
63% 1 2 (66%) 3
56% 0 2 (100%) 2
50% 0 1 (100%) 1
Total 62 37 99
*
Results after adjudication
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Table 4
Evidence Tiers for Stage II.
Tier Reference Type
1 Evidence from a systematic review, or a meta-analysis, or a clinical practice guideline clearly based on a systematic review1.
2
Evidence from clinical practice guidelines or broad-based expert consensus with some level of evidence review, but using unclear 
methods or using sources that were not systematically identified1.
3 Evidence from another reference with non-systematic review of evidence (e.g., GeneTest Reviews, OrphaNet, and Clinical Utility Gene Cards, opinion of a single or few (<5) experts) with additional primary literature cited.
4 Evidence from another reference with non-systematic review of evidence (e.g., GeneTest Reviews, OrphaNet, and Clinical Utility Gene Cards, opinion of a single or few (<5) experts) with no citations to primary data sources.
1
systematic review of the evidence means that traditional systematic review methods are followed including: a) a clearly stated set of objectives, b) 
an explicit, reproducible methodology, c) systematic search that attempts to identify all studies that would meet the eligibility criteria, d) inclusion 
and exclusion criteria for studies are pre-defined, and e) an assessment of the validity of findings in the included studies, and f) a systematic 
presentation and synthesis of the characteristics and findings of the included studies.40
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Table 5
Identified References for Three Case Studies in Stage II.
FAP HH AAT Deficiency
Total Number of References Identified 46 34 31
Number of Related References 28 13 16
Number of References in Each Tier
 Tier 1 14 5 8
 Tier 2 11 2 4
 Tier 3 or 4 3 6 4
Number of References Cited 5 10 8
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